Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $71,181.37 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the sale, the chief executive officer directly owned 135,209 shares in the company, valued at $4,200,943.63. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Monday, May 18th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $29.22, for a total value of $66,972.24.
• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $28.60, for a total value of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Stock Performance

Shares of PHVS stock opened at $32.80 on Friday. Pharvaris N.V. has a 1 year low of $16.72 and a 1 year high of $34.41. The firm’s fifty day simple moving average is $30.02 and its 200 day simple moving average is $27.74. The firm has a market capitalization of $2.15 billion, a P/E ratio of -10.31 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts anticipate that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. UBS Group set a $74.00 price objective on shares of Pharvaris in a research note on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wedbush increased their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $49.18.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of Pharvaris in the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Pharvaris in the third quarter worth $75,000. Barclays PLC acquired a new position in Pharvaris in the fourth quarter worth $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pharvaris during the fourth quarter worth $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.